A 2025 survey highlights growing momentum for multi-indication drug development, with opportunities in innovative trial design, targeted patient selection, and real-world evidence to speed label expansion.
Alan Baldridge, MD
Advertisement
Senior Director, Gastroenterology and Hepatology, Drug Development Solutions, ICON
Articles by Alan Baldridge, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: AI-Driven Oversight, Biotech Acceleration Strategies, and a Major Win in Bladder Cancer
2
Honing the Power of AI for Next Generation Trial Oversight and Execution
3
Genentech’s Phase III MEERKAT and SANDCAT Trials Show Vision and Anatomical Gains With Vamikibart in Uveitic Macular Edema
4
A Look Back: AI and Pragmatic Trials Took Center Stage at SCOPE Summit 2025
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
